IFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:

Veldhuis et al.

Serial No.: 10/678,957

Filed: October 3, 2003

For: AT LEAST PARTIAL PREVENTION AND/OR REDUCTION OF CELLULAR DAMAGE IN TISSUE THAT HAS SUFFERED FROM OR IS SUFFERING FROM HYPOXIA AND/OR ISCHAEMIA AND/OR INFLAMMATION

Confirmation No.: 7282

Examiner: To be assigned

Group Art Unit: 1641

Attorney Docket No.: 2183-6141US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

February 10, 2005

Aubry Blackburn

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

Serial No.: 10/678,957

Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>
WO 02 080953 A2	10-17-2002	Universitair Medisch Centrum
		Utrecht
WO 02 080959 A1	10-17-2002	Universitair Medisch Centrum
		Utrecht

Other Documents

LIU et al., Interferon-B administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia, Neuroscience Letters, 2002, pp. 146-48, Vol. 327.

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041 Attorney for Applicant(s)

TraskBritt, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: February 7, 2005

ACT/bv

Enclosures: Form PTO/SB/08

Cited Documents

Document in ProLaw

DTA	ICD II		(10	٠.
PTO	/3B/(JOAI	110-	VI.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known 10/678,957 INFORMATION DISCLOSURE Application Number Filing Date October 3, 2003 **CATEMENT BY APPLICANT** First Named Inventor Veldhuis et al. Group Art Unit 1641 (use as many sheets as necessary) Examiner Name To be assigned of 2 2183-6141US Attorney Docket Number

Examiner Cite Initials * No.1		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	
		Number - Kind Code ² (if known)		Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	T	US-			-
		US-			
	1	US-			
		US-			
		US-		·	
		US-			

		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 02 080953 A2	10-17-2002	Universitair Medisch Centrum Utrecht		
		WO 02 080959 A1	10-17-2002	Universitair Medisch Centrum Utrecht		
			<u> </u>			

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

1021

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DIGGLOCUDE	Application Number	10/678,957	
INFORMATION DISCLOSURE	Filing Date	October 3, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Veldhuis et al.	
	Group Art Unit	1641	
(use as many sheets as necessary)	Examiner Name	To be assigned	
Sheet 2 of 2	Attorney Docket Number	2183-6141US	

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
		LIU et al., Interferon-B administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia, Neuroscience Letters, 2002, pp. 146-48, Vol. 327.			
-					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.